<DOC>
	<DOCNO>NCT00819780</DOCNO>
	<brief_summary>The primary objective study estimate treatment effect progression-free survival ( PFS ) panitumumab relative bevacizumab combination mFOLFOX6 chemotherapy first-line therapy patient tumor express wild-type KRAS , unresectable mCRC .</brief_summary>
	<brief_title>PEAK : Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 First Line Treatment Metastatic Colorectal Cancer ( mCRC ) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus ( KRAS ) Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologicallyconfirmed adenocarcinoma colon rectum patient unresectable metastatic ( M1 ) disease Patients least 1 unidimensionally measurable lesion least 10 mm per modify Response Evaluation Criteria Solid Tumors ( RECIST ) guideline Wildtype KRAS tumor status confirm Amgen approve central laboratory experience laboratory ( local laboratory ) per local regulatory guideline use validated test method Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Men woman 18 year age old Adequate hematologic , renal , hepatic , metabolic , coagulation function History prior concurrent central nervous system ( CNS ) metastases Prior chemotherapy systemic anticancer therapy treatment metastatic colorectal carcinoma Clinically significant cardiac disease Clinically significant peripheral sensory neuropathy Active inflammatory bowel disease Recent gastroduodenal ulcer active uncontrolled History interstitial lung disease Recent pulmonary embolism , deep vein thrombosis , significant venous event Preexisting bleed diathesis and/or coagulopathy exception wellcontrolled anticoagulation therapy Recent major surgical procedure , open biopsy , significant traumatic injury yet recover prior major surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>modify FOLFOX 6</keyword>
	<keyword>mFOLFOX 6</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>First-Line</keyword>
	<keyword>metastatic</keyword>
</DOC>